Hematological and molecular findings of patients at their first evaluation
| . | Polycythemia vera (n = 15) . | Essential thrombocythemia (n = 12) . | Primary myelofibrosis (n = 15) . |
|---|---|---|---|
| Males/females, n | 9/6 | 4/8 | 9/6 |
| Age, y | |||
| Mean | 54.9 | 54.3 | 55 |
| Median (range) | 59 (27-70) | 56 (25-76) | 55 (31-72) |
| WBC count, × 109/L | |||
| Mean | 11.83 | 8.11 | 11.28 |
| Median (range) | 10.7 (6.70-18.00) | 7.50 (4.18-14.06) | 10.5 (4.3-24.1) |
| Hb, g/dL | |||
| Mean | 18.1 | 14 | 12.4 |
| Median (range) | 17.1 (14.8-24.8) | 14 (12.6-15.6) | 12.8 (7.9-19.4) |
| PLT count, × 109/L | |||
| Mean | 504 | 672 | 621 |
| Median (range) | 518 (205-849) | 604 (456-970) | 529 (58-2.696) |
| JAK2V617F or MPLW515K positive, n (%) | 13 (87) | 7 (58) | 11 (73) |
| SOCS methylation, n (%) | 5 (28) | 3 (27) | 8 (47) |
| . | Polycythemia vera (n = 15) . | Essential thrombocythemia (n = 12) . | Primary myelofibrosis (n = 15) . |
|---|---|---|---|
| Males/females, n | 9/6 | 4/8 | 9/6 |
| Age, y | |||
| Mean | 54.9 | 54.3 | 55 |
| Median (range) | 59 (27-70) | 56 (25-76) | 55 (31-72) |
| WBC count, × 109/L | |||
| Mean | 11.83 | 8.11 | 11.28 |
| Median (range) | 10.7 (6.70-18.00) | 7.50 (4.18-14.06) | 10.5 (4.3-24.1) |
| Hb, g/dL | |||
| Mean | 18.1 | 14 | 12.4 |
| Median (range) | 17.1 (14.8-24.8) | 14 (12.6-15.6) | 12.8 (7.9-19.4) |
| PLT count, × 109/L | |||
| Mean | 504 | 672 | 621 |
| Median (range) | 518 (205-849) | 604 (456-970) | 529 (58-2.696) |
| JAK2V617F or MPLW515K positive, n (%) | 13 (87) | 7 (58) | 11 (73) |
| SOCS methylation, n (%) | 5 (28) | 3 (27) | 8 (47) |
WBC indicates white blood cell; Hb, hemoglobin; and PLT, platelet.